Why AstraZeneca Is a Better Investment Than Johnson & Johnson

Based on the article, the author suggests investing in AstraZeneca instead of Johnson & Johnson due to several reasons. Firstly, AstraZeneca has a stronger growth rate and more diverse business compared to Johnson & Johnson’s, which continually faces legal problems. In the most recent quarterly results, AstraZeneca reported a 19% increase in revenue, while Johnson & Johnson is targeting growth between 5% and 7% only. Secondly, AstraZeneca’s stock may be slightly more expensive than Johnson & Johnson’s, but it is worth the premium due to its solid long-term prospects, reliable dividend, and lack of major legal issues. Lastly, while Johnson & Johnson offers a higher dividend yield, AstraZeneca’s stock has performed better over the years, indicating a lower yield due to stronger returns. Overall, the author argues that AstraZeneca’s future looks brighter than Johnson & Johnson’s, making it a better investment choice. However, it should be noted that the author holds no positions in either company.